More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...

A surge in deals and financings had the industry abuzz heading into this year’s J.P Morgan Healthcare Conference. But some ...

With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

By the end of March, the agency could approve multiple “national priority” voucher winners, as well as a gene therapy it ...

Co-founded by Jennifer Doudna and Fyodor Urnov, the company intends to simultaneously develop many gene editing treatments ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...